{"entity":{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","aka":["TARMAC"],"tldr":"A phase 2 trial of cyclophosphamide, epirubicin, docetaxel, carboplatin and other drugs in triple-negative breast cancer, run by University of Chicago, now recruiting.","summary":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06291064 by University of Chicago, with a registry enrolment figure of 85 participants, started 2025-03-18 and due to reach its primary completion in 2029-06. Interventions recorded: Cyclophosphamide; Epirubicin; Docetaxel; Carboplatin; Breast Surgery; Capecitabine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC)\". Sites: Nigeria. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06291064","url":"https://clinicaltrials.gov/study/NCT06291064"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cyclophosphamide","epirubicin","docetaxel","carboplatin","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06291064","phase":"2","setting":"TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)","sponsor":"University of Chicago","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06291064/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}